1. Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer: effectiveness and value : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, September 28, 2017 Subject(s): Ovarian Neoplasms -- drug therapyPoly(ADP-ribose) Polymerase Inhibitors -- therapeutic useComparative Effectiveness ResearchPoly(ADP-ribose) Polymerase Inhibitors -- adverse effectsPoly(ADP-ribose) Polymerase Inhibitors -- economicsTreatment OutcomeHumansUnited States
